Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (E3393)

Barbara A. Murphy, Traci Leong, Brian Burkey, Corey Langer, Arlene A. Forastiere

Research output: Contribution to journalArticle

Abstract

Recurrent or metastatic squamous carcinoma of the head and neck (RMSCHN) is a modestly chemoresponsive tumor; however, currently available agents have failed to improve survival. New active agents are needed for the treatment of this disease. Topotecan is a topoisomerase inhibitor that demonstrated initial promising activity in squamous carcinoma of the head and neck. The Eastern Cooperative Oncology Group conducted a phase II trial of topotecan to determine the efficacy and toxicity of a weekly treatment schedule in patients with RMSCHN. Patients with metastatic or locally recurrent squamous carcinoma of the head and neck were treated with topotecan 1.5 mg/m2 × 24 hours by continuous infusion on days 1, 8, 15, and 22 of each 35-day cycle. Patients were stratified in two cohorts: chemonaive and previously treated. Sixteen chemonaive and 16 previously treated patients were registered on study. Grade III/IV neutropenia and anemia occurred in 16% and 18% of patients, respectively. No responses were observed in either cohort. Median survival for previously untreated patients was 4.6 months and 3.2 months for previously treated patients. Topotecan failed to demonstrate efficacy in patients with RMSCHN. Further evaluation of this agent is not planned.

Original languageEnglish (US)
Pages (from-to)64-66
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume24
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Topotecan
Squamous Cell Carcinoma
Neck
Head
Therapeutics
Topoisomerase Inhibitors
Survival
Neutropenia
Anemia
Appointments and Schedules

Keywords

  • Head and neck cancer
  • Metastatic disease
  • Squamous carcinoma
  • Topotecan
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{5579b0c6446440fc9518fd796d7f6623,
title = "Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (E3393)",
abstract = "Recurrent or metastatic squamous carcinoma of the head and neck (RMSCHN) is a modestly chemoresponsive tumor; however, currently available agents have failed to improve survival. New active agents are needed for the treatment of this disease. Topotecan is a topoisomerase inhibitor that demonstrated initial promising activity in squamous carcinoma of the head and neck. The Eastern Cooperative Oncology Group conducted a phase II trial of topotecan to determine the efficacy and toxicity of a weekly treatment schedule in patients with RMSCHN. Patients with metastatic or locally recurrent squamous carcinoma of the head and neck were treated with topotecan 1.5 mg/m2 × 24 hours by continuous infusion on days 1, 8, 15, and 22 of each 35-day cycle. Patients were stratified in two cohorts: chemonaive and previously treated. Sixteen chemonaive and 16 previously treated patients were registered on study. Grade III/IV neutropenia and anemia occurred in 16{\%} and 18{\%} of patients, respectively. No responses were observed in either cohort. Median survival for previously untreated patients was 4.6 months and 3.2 months for previously treated patients. Topotecan failed to demonstrate efficacy in patients with RMSCHN. Further evaluation of this agent is not planned.",
keywords = "Head and neck cancer, Metastatic disease, Squamous carcinoma, Topotecan, Treatment",
author = "Murphy, {Barbara A.} and Traci Leong and Brian Burkey and Corey Langer and Forastiere, {Arlene A.}",
year = "2001",
doi = "10.1097/00000421-200102000-00011",
language = "English (US)",
volume = "24",
pages = "64--66",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck

T2 - An Eastern Cooperative Oncology Group trial (E3393)

AU - Murphy, Barbara A.

AU - Leong, Traci

AU - Burkey, Brian

AU - Langer, Corey

AU - Forastiere, Arlene A.

PY - 2001

Y1 - 2001

N2 - Recurrent or metastatic squamous carcinoma of the head and neck (RMSCHN) is a modestly chemoresponsive tumor; however, currently available agents have failed to improve survival. New active agents are needed for the treatment of this disease. Topotecan is a topoisomerase inhibitor that demonstrated initial promising activity in squamous carcinoma of the head and neck. The Eastern Cooperative Oncology Group conducted a phase II trial of topotecan to determine the efficacy and toxicity of a weekly treatment schedule in patients with RMSCHN. Patients with metastatic or locally recurrent squamous carcinoma of the head and neck were treated with topotecan 1.5 mg/m2 × 24 hours by continuous infusion on days 1, 8, 15, and 22 of each 35-day cycle. Patients were stratified in two cohorts: chemonaive and previously treated. Sixteen chemonaive and 16 previously treated patients were registered on study. Grade III/IV neutropenia and anemia occurred in 16% and 18% of patients, respectively. No responses were observed in either cohort. Median survival for previously untreated patients was 4.6 months and 3.2 months for previously treated patients. Topotecan failed to demonstrate efficacy in patients with RMSCHN. Further evaluation of this agent is not planned.

AB - Recurrent or metastatic squamous carcinoma of the head and neck (RMSCHN) is a modestly chemoresponsive tumor; however, currently available agents have failed to improve survival. New active agents are needed for the treatment of this disease. Topotecan is a topoisomerase inhibitor that demonstrated initial promising activity in squamous carcinoma of the head and neck. The Eastern Cooperative Oncology Group conducted a phase II trial of topotecan to determine the efficacy and toxicity of a weekly treatment schedule in patients with RMSCHN. Patients with metastatic or locally recurrent squamous carcinoma of the head and neck were treated with topotecan 1.5 mg/m2 × 24 hours by continuous infusion on days 1, 8, 15, and 22 of each 35-day cycle. Patients were stratified in two cohorts: chemonaive and previously treated. Sixteen chemonaive and 16 previously treated patients were registered on study. Grade III/IV neutropenia and anemia occurred in 16% and 18% of patients, respectively. No responses were observed in either cohort. Median survival for previously untreated patients was 4.6 months and 3.2 months for previously treated patients. Topotecan failed to demonstrate efficacy in patients with RMSCHN. Further evaluation of this agent is not planned.

KW - Head and neck cancer

KW - Metastatic disease

KW - Squamous carcinoma

KW - Topotecan

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0035113966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035113966&partnerID=8YFLogxK

U2 - 10.1097/00000421-200102000-00011

DO - 10.1097/00000421-200102000-00011

M3 - Article

C2 - 11232952

AN - SCOPUS:0035113966

VL - 24

SP - 64

EP - 66

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -